Professor, Pediatrics, Ohio State University College of Medicine
Neurology
Dr. Kevin M. Flanigan, MD
|
|
Give Review
Doctor Kevin M. Flanigan, MD works in the field of Neurology. He researched medicine at Rush Medical College. Kevin M. Flanigan is a published MD. He has 43 publications published. The most current publication "Dp412e: a novel human embryonic dystrophin isoform induced by BMP4 in early differentiated cells."
Publications
- The first exon duplication mouse model of Duchenne muscular dystrophy: A tool for therapeutic development.
- Reliability and validity of ACTIVE-seated: An outcome in dystrophinopathy.
- Sanfilippo syndrome registry project and natural history studies: an example of patients, parents and researchers collaborating for a cure.
- Visual Diagnosis: Chest Pain in a Boy With Duchenne Muscular Dystrophy and Cardiomyopathy.
- A Phase I/IIa Follistatin Gene Therapy Trial for Becker Muscular Dystrophy.
- Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice.
- Outcome reliability in non-Ambulatory Boys/Men with duchenne muscular dystrophy.
- Ataluren treatment of patients with nonsense mutation dystrophinopathy.
- Duchenne and Becker Muscular Dystrophies.
- One Year Outcome of Boys With Duchenne Muscular Dystrophy Using the Bayley-III Scales of Infant and Toddler Development.
- Cryptic MHC class I-binding peptides are revealed by aminoglycoside-induced stop codon read-through into the 3' UTR.
- Feasibility and Safety of Systemic rAAV9-hNAGLU Delivery for Treating Mucopolysaccharidosis IIIB: Toxicology, Biodistribution, and Immunological Assessments in Primates.
- Dystrophin as a therapeutic biomarker: Are we ignoring data from the past?
- Feasibility and Safety of Systemic rAAV9-hNAGLU Delivery for Treating MPS IIIB: Toxicology, Bio-distribution and Immunological Assessments in Primates.
- Dexmedetomidine and ketamine sedation for muscle biopsies in patients with Duchenne muscular dystrophy.
- A comparative study of N-glycolylneuraminic acid (Neu5Gc) and cytotoxic T cell (CT) carbohydrate expression in normal and dystrophin-deficient dog and human skeletal m...
- Exome sequencing identifies a DNAJB6 mutation in a family with dominantly-inherited limb-girdle muscular dystrophy.
- The 2-min walk test is sufficient for evaluating walking abilities in sporadic inclusion body myositis.
- The ZZ Domain of Dystrophin in DMD: Making Sense of Missense Mutations.
- Recurrent central nervous system white matter changes in charcot-marie-tooth type X.
- Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: Results of a double-blind randomized clinical trial.
- Anti-dystrophin T cell responses in duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect.
- Position of glycine substitutions in the triple helix of COL6A1, COL6A2, and COL6A3 is correlated with severity and mode of inheritance in collagen VI myopathies.
- Eteplirsen for the treatment of duchenne muscular dystrophy.
- Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network.
- Correlation of knee strength to functional outcomes in becker muscular dystrophy.
- Proof of concept of the ability of the kinect to quantify upper extremity function in dystrophinopathy.
- Precordial R Wave Height Does Not Correlate with Echocardiographic Findings in Boys with Duchenne Muscular Dystrophy.
- LTBP4 genotype predicts age of ambulatory loss in duchenne muscular dystrophy.
- Cardiac management in neuromuscular diseases.
- Camptocormia as a late presentation in a manifesting carrier of duchenne muscular dystrophy.
- A practical approach to molecular diagnostic testing in neuromuscular diseases.
- RNA Interference Inhibits DUX4-induced Muscle Toxicity In Vivo: Implications for a Targeted FSHD Therapy.
- Effects of Angiotensin-Converting Enzyme Inhibitors and/or Beta Blockers on the Cardiomyopathy in Duchenne Muscular Dystrophy.
- Evidence-based path to newborn screening for duchenne muscular dystrophy.
- A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy.
- Abnormal expression of mu-crystallin in facioscapulohumeral muscular dystrophy.
- Sarcolemmal reorganization in facioscapulohumeral muscular dystrophy.
- Dp412e: a novel human embryonic dystrophin isoform induced by BMP4 in early differentiated cells.
- A randomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in duchenne muscular dystrophy.
- Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation duchenne muscular dystrophy.
- Identification of new dystroglycan complexes in skeletal muscle.
Schools
Rush Medical College Of Rush University
Johns Hopkins University School Med
University Of Mi Hosps and Health Ctrs
Procedures Preformed
- EEG (Electroencephalogram)
Conditions Treated
- Cerebral Artery Thrombosis
- Chronic Inflammatory Demyelinating Polyneuritis
- Stroke
Doctors Specialties
- Neurology
- Neuromuscular Medicine
- Pediatric Neurology
- Pediatrics
Accepted Insurances
Education
-
Johns Hopkins University -
University of Michigan Hospitals and Health Centers -
Rush Medical College
Hospital
-
Nationwide Children's Hospital
